- Company name
- BioNTech
- Sector
- Biotechnology: cancer medicines and mRNA vaccines
- About
- BioNTech SE (BioNTech) is based in Mainz, Germany. It develops medicines for cancer and other serious diseases. Its marketed product is the COVID-19 vaccine Comirnaty, which it sells with Pfizer. Its cancer pipeline has three main types: immunomodulators, such as pumitamig, a bispecific antibody against PD-L1 and VEGF-A that it develops with Bristol Myers Squibb (BMS), antibody-drug conjugates, and mRNA cancer immunotherapies. It bought CureVac in December 2025. Revenues were €1,289.2 million in Q3 2026 and €1,512.9 million for nine months. The American Depositary Shares (ADSs) trade on Nasdaq in US dollars, and each ADS represents one ordinary share. BioNTech reports in euros under IFRS. It files a 20-F each year and furnishes quarterly reports on Form 6-K.
- Thesis
- The price of BioNTech depends on whether its cancer pipeline can replace the falling revenue of its COVID-19 vaccine before its cash runs down. COVID-19 vaccine revenues were €673.2 million for the first nine months of 2026, against €1,139.6 million a year before, and the net loss was €1,168.2 million. Cash, cash equivalents and security investments were €16,163.8 million at September 30, 2026, which is most of the value of the company. For the price to rise, four things must be true. Pumitamig must show a clear benefit in its seven pivotal trials. Other late-stage programs, such as gotistobart in lung cancer, must give positive data, after the weak results for trastuzumab pamirtecan in breast cancer and for BNT113 in head and neck cancer in October 2026. Spending must stay inside the guidance for research and for sales and administration. The new chief executive, Guido Oelkers, who starts by February 1, 2027, must keep spending on the best programs. The first interim analysis of the gotistobart Phase 3 trial, expected in 2026, and the Q4 2026 report on March 2, 2027 are the next tests. If more trials fail, the market can value the company at little more than its cash.
- Risks
- Most of the value beyond cash depends on trials. Two late-stage readouts in October 2026 were weak: trastuzumab pamirtecan gave a modest gain with more lung side effects, and BNT113 did not improve progression-free survival. Pumitamig carries the largest part of the pipeline value.
COVID-19 vaccine revenue keeps falling. It was €673.2 million for nine months of 2026, against €1,139.6 million, and demand depends on vaccine recommendations each season.
Patent cases about Comirnaty are open. Moderna, Arbutus and Genevant, and GSK have lawsuits against BioNTech and Pfizer in the United States, Europe and other countries, and a loss can lead to damages or royalties.
The European Commission audits an advance payment of €450 million that CureVac received in 2020. BioNTech says that it cannot exclude a repayment of part or all of it.
The leaders change. Guido Oelkers replaces co-founder Ugur Sahin as chief executive by February 1, 2027, and the search for a new chief medical officer continues.
- Balance sheet
- Cash: €16.2B
Debt: €360M
Net cash: €15.8B
Debt due within 12 months: €104M
At September 30, 2026, BioNTech had cash and cash equivalents of €10,200.8 million, current security investments of €4,390.2 million and non-current security investments of €1,572.8 million, which is €16,163.8 million in all. Debt in the figures is lease liabilities, loans and borrowings of €359.8 million, of which €104.4 million is current. Total equity was €17,711.7 million. Cash used in operating activities was €540.3 million for nine months, and payments for share repurchases were €403.5 million.
As of Sep 30, 2026.
- Checkpoints
- Dec 2026 (estimate): Gotistobart Phase 3 interim analysis. Pending. Watch: The independent data monitoring committee recommends to unblind PRESERVE-003 because of a survival benefit, and this passes; a stop for futility fails.
Mar 2, 2027: Q4 2026 results and 2027 guidance. Pending. Watch: 2026 revenue is in the guided range of €1.7 billion to €1.9 billion and the 2027 guidance keeps costs near the 2026 level, and this passes; revenue below €1.7 billion or much higher costs fail.
- Recent events
- Nov 10, 2026: BioNTech agreed to buy an FDA priority review voucher from Scholar Rock for $205 million in cash. It plans to use the voucher for a future filing of a late-stage cancer medicine.
Nov 3, 2026: BioNTech reported Q3 2026 results. Revenues were €1,289.2 million, against €1,518.9 million, and net profit was €184.5 million. It narrowed its 2026 revenue guidance to €1.7 billion to €1.9 billion. It bought back 5,037,452 ADSs for $463.3 million under its $1.0 billion program through September 30, 2026. It will hand future research costs of one program to Roche and Genentech from January 1, 2027, for royalties.
Oct 26, 2026: BioNTech and DualityBio said that the Phase 3 trial DYNASTY-Breast02 of trastuzumab pamirtecan met its primary endpoint, but the gain in progression-free survival was modest and more patients had interstitial lung disease. The companies said that the benefit to patients would be limited in this breast cancer setting.
Oct 13, 2026: In the Phase 2/3 trial AHEAD-MERIT in head and neck cancer, BNT113 with pembrolizumab did not improve progression-free survival against pembrolizumab alone. The trial continues to test overall survival, its second primary endpoint.
Aug 3, 2026: The Supervisory Board appointed Guido Oelkers, the chief executive of Sobi, as chief executive of BioNTech from February 1, 2027 at the latest. He replaces co-founder Ugur Sahin. Chief medical officer Özlem Türeci will leave to lead a new company with Ugur Sahin.